[1]陈婉琼 林少梅 陈明珠 张飞燕.基于网络药理学探讨贞芪扶正胶囊抗非小细胞肺癌的作用机制[J].大众科技,2022,24(09):133-137.
　Exploration on the Mechanism of Zhenqi Fuzheng Capsule in the Treatment of Non-Small Cell Lung Cancer Based on Network Pharmacology[J].Popular Science & Technology,2022,24(09):133-137.
点击复制

基于网络药理学探讨贞芪扶正胶囊 抗非小细胞肺癌的作用机制()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
24
期数:
2022年09
页码:
133-137
栏目:
医药与卫生
出版日期:
2022-09-20

文章信息/Info

Title:
Exploration on the Mechanism of Zhenqi Fuzheng Capsule in the Treatment of Non-Small Cell Lung Cancer Based on Network Pharmacology
作者:
陈婉琼 林少梅 陈明珠 张飞燕　
（泉州医学高等专科学校药学院，福建 泉州 362011）
关键词:
贞芪扶正胶囊; 非小细胞肺癌; 网络药理学; 作用机制
Keywords:
Zhenqi Fuzheng capsule non-small cell lung cancer (NSCLC) network pharmacology mechanism of action
文献标志码:
A
摘要:
目的：基于网络药理学探讨贞芪扶正胶囊抗非小细胞肺癌（NSCLC）潜在的作用机制。方法：使用TCMSP数据库和PubChem数据库预测贞芪扶正胶囊作用靶点；使用GeneCards数据库和OMIM数据库预测NSCLC疾病靶点；应用Cytoscape软件构建“活性成分-靶点”网络筛选贞芪扶正胶囊抗NSCLC关键成分；使用String数据库和Cytoscape软件构建共同靶点的PPI网络图，筛选核心靶点；采用Metascape数据库对共同靶点进行GO和KEGG富集分析。结果：得到有效成分26个，共同靶点139个，主要富集在6299个GO条目及256条KEGG通路中。结论：贞芪扶正胶囊通过多成分、多靶标、多通路治疗NSCLC，为其进一步机制研究提供理论支持。
Abstract:
Objective: To explore the potential mechanism of Zhenqi Fuzheng capsule in the treatment of non-small cell lung cancer (NSCLC) base on network pharmacology. Methods: TCMSP database and PubChem database were used to predict the action target of Zhenqi Fuzheng capsule Genecards database and OMIM database were used to predict NSCLC disease targets the "active ingredient target" network was constructed by using Cytoscape software to screen the key components of Zhenqi Fuzheng capsule in the treatment of NSCLC use String database and Cytoscape software to build PPI network diagram of common targets and screen core targets Metascape database was used for GO and KEGG enrichment analysis of common targets. Results: 26 active ingredients and 139 common targets were obtained, which were mainly enriched in 6299 GO entries and 256 KEGG pathways. Conclusion: Zhenqi Fuzheng capsule can treat NSCLC through multiple component, multiple target and multiple pathway, which provides theoretical support for its further mechanism research.

参考文献/References:

[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2020[J]. CA: A Cancer Journal for Clinicians, 2020, 70(1): 7-30. [2] Khunger M, Patil P D, Khunger A, et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients[J]. PLoS ONE, 2018, 13(10): e0197743. [3] Tao L, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades[J]. Cancer Management and Research, 2019(11): 943-953. [4] 张豪健，张红，赵丽霞. 贞芪扶正胶囊联合化疗治疗非小细胞肺癌有效性和安全性的Meta分析[J]. 中国研究型医院，2021，8(2): 50-56. [5] 吴安妮，袁力，邢婧，等. 黄芪甲苷对非小细胞肺癌细胞A549，SPC-A1增殖凋亡的调控作用及其机制[J]. 山东医药，2021，61(3): 18-22. [6] 舒文，于廷和. 贞芪扶正胶囊在卵巢癌化疗并发症预防中的效果观察[J]. 中药药理与临床，2016，32(6): 201-204. [7] 冯滢滢，李军，刘泉龙，等. 贞芪扶正胶囊辅助大肠癌术后化疗临床观察[J]. 北京中医药，2015，34(10): 810-812. [8] 徐智敏，杨凤娇. 贞芪扶正胶囊对老年化疗患者生活质量及免疫功能的影响[J]. 中外医学研究，2019，17(4): 50-52. [9] 江奋霞，徐爱国，张茜，等. 贞芪扶正胶囊对晚期非小细胞肺癌患者免疫功能，生存质量，化疗不良反应的影响[J]. 现代中西医结合杂志，2019，28(35): 3926-3929. [10] 孔颖泽，孙毅，冷嘉兴，等. 贞芪扶正胶囊配合化疗治疗晚期非小细胞肺癌疗效观察[J]. 辽宁中医杂志，2005，32(9): 872-873. [11] Lee S H, Lee E J, Min K H, et al. Quercetin enhances chemo-sensitivity to gemcitabine in lung cancer cells by inhibiting heatshock protein 70 expression[J]. Clinical Lung Cancer, 2015, 16(6): e235-e243. [12] Mukherjee A, Khuda-Bukhsh A R. Quercetin Down-regulates IL-6/STAT-3 Signals to Induce Mitochondrial-mediated Apoptosis in a Nonsmall-cell Lung-cancer Cell Line, A549[J]. Journal of Pharmacopuncture, 2015, 18(1): 19-26. [13] 王静，袁媛，潘跃银，等. 吉非替尼联合槲皮素对非小细胞肺癌PC9/GR细胞增殖的协同抑制作用[J]. 肿瘤，2018，38(3): 182-188. [14] 刘伟，李蔷薇，王静，等. 奥希替尼联合槲皮素对H1975细胞增殖的协同抑制作用[J]. 安徽医科大学学报，2019(8): 1184-1188. [15] Wang H, Chen L, Zhang X, et al. Kaempferol protects mice from d-GalN/LPS-induced acute liver failure by regulating the ER stress-Grp78-CHOP signaling pathway[J]. Biomedicine and Pharmacotherapy, 2019, 111: 468-475. [16] Han X, Liu CF, Gao N, et al. Kaempferol suppresses proliferation but increases apoptosis and autophagy by up-regulating microRNA-340 in human lung cancer cells[J]. Biomedecine and Pharmacotherapie, 2018, 108: 809-816. [17] 杨生辉，黄琰菁，莫安薇，等. 山奈酚通过调控miR21抑制非小细胞肺癌A549细胞增殖的研究[J]. 中国现代应用药学，2020，37(13): 1557-1562. [18] 阮君山，周欢，蒋宗胜，等. 木犀草素调控非小细胞肺癌上皮间质转化的分子机制[J]. 医药导报，2018，37(1): 20-26. [19] 刘玉霞，郑心，梁冉冉，等. 黄芪甲苷基于ILT4-PI3KAkt-B7-H3通路对NSCLC免疫逃逸机制的实验研究[J/OL]. 中药材，2021(11): 2687-2692. [20] 李爱明，赵惠民，揭俊卿. 芒柄花黄素对非小细胞肺癌A549细胞增殖及上皮间质转化的抑制作用[J]. 临床肿瘤学杂志，2015，20(6): 481-486. [21] Hu C, He Y. Formononetin inhibits non-small cell lung cancer proliferation via regulation of mir-27a-3p through p53 Pathway[J]. Oncologie, 2021, 23(2): 241-250. [22] Nazaryan-Petersen L, Bjerregaard V A, Nielsen F C, et al. Chromothripsis and DNA repair disorders[J]. Journal of Clinical Medicine, 2020, 9(3): 7141117. [23] Pérez-Ramírez C, Adas-Garre M, Alnatsha A, et al. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients[J]. Pharmacogenomics Journal, 2019, 19(2):164-177. [24] Ciocca D R, Calderwood S K. Heat-shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications[J]. Cell Stress Chaperones, 2005, 10(2): 86-103． [25] 张翠红，夏云亚，胡佩，等. 血清肿瘤标志物联合Ki-67、HSP90α检测肺癌的诊断价值及临床意义[J]. 国际检验医学杂志，2019，40(8): 987-990. [26] 李耀杰，汤素娜，王保收，等. miR-105-5p靶向MAPK1抑制非小细胞肺癌细胞A549的生长，运动和上皮间质转化[J]. 中国免疫学杂志，2020，36(20): 2485-2490. [27] Osoegawa A, Yoshino I, Kometani T, et al. Overexpression of jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features[J]. Cancer, 2006, 107(1): 154-161. [28] 马国栋，刘志勇，邹卫，等. 核转录因子kB在非小细胞肺癌中的表达及意义[J]. 临床肺科杂志，2008，13(9): 1178-1180. [29] Li Y, Song X, Niu J, et al. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer[J]. Archives of Biochemistry and Biophysics, 2021, 701: 108818. [30] Chen Q Y, Costa M. PI3K/Akt/mTOR Signaling pathway and the biphasic effect of arsenic in carcinogenesis[J]. Molecular Pharmacology, 2018, 118: 112268. [31] 杨艳荣，郑先雷，李洪洋. AKT1表达与非小细胞肺癌临床病理特征及预后的关系[J]. 实用癌症杂志，2021，36(3): 364-367. [32] Peng J W, Liu D Y, Lin G N, et al. Hepatitis B virus infection is associated with poor prognosis in patients with advanced non small cell lung cancer[J]. Asian Pacific Journal of Cancer Prevention, 2015, 16(13): 5285-5288. [33] Domen A, Deben C, Hermans C, et al. 1178P Senescence signature affects overall survival in non-small cell lung cancer[J]. Annals of Oncology, 2021, 32(S5): 943. [34] Zhou F, Geng J, Xu S, et al. FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC[J]. Aging, 2019, 11(16): 6069-6088. [35] Zhao, D, Zhang T, Hou X M, et al. Knockdown of fascin-1 expression suppresses cell migration and invasion of non-small cell lung cancer by regulating the MAPK pathway[J]. Biochemical and Biophysical Research Communications, 2018, 497(2): 694-699. [36] Shen F, Ge C, Yuan P. Aloe-emodin induces autophagy and apoptotic cell death in non-small cell lung cancer cells via Akt/mTOR and MAPK signaling[J]. European Journal of Pharmacology, 2020, 886: 173550. [37] Lau E S, Paniagua S M, Liu E, et al. Cardiovascular risk factors are associated with future cancer[J]. JACC CardioOncology, 2021, 3(1): 48-58. [38] Fl?er R A, Atosa E, Cui H L, et al. Impact of human cytomegalovirus infection and its immune response on survival of patients with ovarian cancer[J]. Translational oncology, 2018, 11(6): 1292-1300. [39] 郭英花，卞美璐. 人类巨细胞病毒与宫颈癌关系的研究进展[J]. 中国妇产科临床杂志，2001(4): 252-253，235. [40] 汤智勇，陈华，李倩，等. 人类巨细胞病毒感染与结肠癌相关关系的初步研究[J]. 实用预防医学，2007(3): 688-690.

备注/Memo

备注/Memo:
【收稿日期】2022-04-08 【作者简介】陈婉琼（1991－），女，福建泉州人，泉州医学高等专科学校药学院助教，研究方向为天然产物药理活性。
更新日期/Last Update: 2022-10-14